Active	Status	Sponsor type	Region	Phase	Filter
20 Active 8 Inactive 28 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Li, Ting
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease	Recruiting	3	440	Europe, Japan, US, RoW	Belimumab, BENLYSTA, GSK1550188, Placebo	GlaxoSmithKline	Lung Diseases, Interstitial	10/28	12/28
NCT06716606: A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease	Recruiting	3	225	RoW	Belimumab	GlaxoSmithKline, ICON plc	Bronchial Diseases	08/28	01/30
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.	Recruiting	2/3	240	Europe, Canada, Japan, US, RoW	EFG PH20 SC, PBO	argenx, argenx BV	Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome	12/26	02/27
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE	Recruiting	2/3	300	Europe, Japan, US, RoW	Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo	GlaxoSmithKline	Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic	07/27	07/27
NCT06711991: A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease	Not yet recruiting	1	48	RoW	TQC3927 powder for inhalation, TQC3927 powder for inhalation placebo	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Chronic Obstructive Pulmonary Disease	12/25	01/26